Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +49.90%
#3 Velvet Velvet +37.98%
#4 DoubleZero DoubleZero +13.36%
#5 Akedo Akedo +13.09%
#6 HOME HOME +12.74%
#7 Cross Cross +12.16%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.82%
#9 XPIN Network XPIN Network +9.85%
#10 Fake World Assets Fake World Assets +9.79%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
GENinCode plc GENinCode plc

GENinCode plc

GENI
Rank in Stocks #41232
GENinCode Plc specializes in the creation and commercialization of advanced... GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Share Price
$0.01208303
Market Cap
$33.79K
Change (1 day)
-1.33%
Change (1 year)
-38.40%
Country
GB
Trade GENinCode plc (GENI)

Category

Healthcare
P/E ratio for GENinCode plc (GENI)
P/E ratio as of 2026 TTM: 0
According to GENinCode plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for GENinCode plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 30.84 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 34.53 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -164.27 -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 40.90 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.